𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation

✍ Scribed by Esther N. M. Nolte-‘t Hoen; Josée P. A. Wagenaar-Hilbers; Elmieke P. J. Boot; Chia-Huey Lin; Ger J. A. Arkesteijn; Willem van Eden; Leonie S. Taams; Marca H. M. Wauben

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
347 KB
Volume
34
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Naturally occurring CD4^+^ regulatory T cells can be identified on the basis of expression of CD25 and suppression of T cell responses in vitro after TCR triggering. Here, we demonstrate that a CD134^+^ subset of CD4^+^CD25^+^ T cells in naive rats suppresses antigen‐specific T cell responses in vitro without additional TCR stimulation. In contrast, CD4^+^CD25^+^CD134^–^ regulatory T cells and total CD4^+^CD25^+^ regulatory T cells have suppressive activity only during simultaneous activation of responder and regulatory T cells or after in vitro pre‐activation. Furthermore CD4^+^CD25^+^CD134^+^ T cells have a more activated phenotype than CD4^+^CD25^+^CD134^–^ T cells, as based on the expression of CD62L, CD45RC, and MHC class II. We propose that the CD134^+^ regulatory T cells contain an in vivo activated and highly suppressive regulatory T cell subset. CD4^+^CD25^+^CD134^+^ T cells can be found in several compartments of the immune system, including spleen, lymph nodes, and blood. Interestingly though, the relative amounts of these cells within the CD4^+^ population and their CD134 expression levels are highest in mucosa‐draining lymph nodes and lowest in blood. This suggests that the presence of CD4^+^CD25^+^CD134^+^ T cells indicates sites of active immune suppression.

📜 SIMILAR VOLUMES

Visualizing the course of antigen-specif
Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor
✍ Ludger Klein; Lydie Trautman; Stelios Psarras; Silke Schnell; Anja Siermann; Rol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB 👁 1 views

## Abstract Spontaneous tumors frequently express antigens that can be recognized by the immune system but nevertheless manage to evade immune surveillance. To better understand the mechanism of evasion, we followed CD8 and CD4 T cells reacting against a subcutaneously growing tumor, modified to ex

B cells engineered to express Fas ligand
B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo
✍ Michele M. Kosiewicz; Anasuya Krishnan; Mark T. Worthington; James A. Matriano; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB 👁 2 views

Inducing apoptosis of activated lymphocytes via Fas ligand (FasL, CD95) may be a useful strategy for the treatment of autoimmune diseases mediated by pathogenic T cells. We propose that B cells may be ideal tools for effective delivery of a FasL-mediated apoptotic signal to pathogenic T cells for a